Cooper Companies (COO) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Cooper Companies (NYSE:COO) announced its quarterly earnings data on Thursday. The medical device company reported $2.86 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.02, Bloomberg Earnings reports. Cooper Companies had a return on equity of 16.90% and a net margin of 7.83%. The company had revenue of $631.30 million during the quarter, compared to analyst estimates of $627.49 million. During the same quarter last year, the firm posted $2.50 EPS. The firm’s revenue for the quarter was up 20.8% on a year-over-year basis. Cooper Companies updated its FY18 guidance to $11.70-11.90 EPS.

Cooper Companies opened at $226.50 on Friday, Marketbeat reports. The company has a quick ratio of 1.61, a current ratio of 2.83 and a debt-to-equity ratio of 0.75. The stock has a market cap of $11.22 billion, a price-to-earnings ratio of 23.35, a P/E/G ratio of 1.81 and a beta of 0.61. Cooper Companies has a twelve month low of $216.47 and a twelve month high of $260.26.

In other news, CEO Robert S. Weiss sold 36,769 shares of Cooper Companies stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $242.35, for a total transaction of $8,910,967.15. Following the completion of the sale, the chief executive officer now owns 135,936 shares in the company, valued at approximately $32,944,089.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Carol R. Kaufman sold 13,362 shares of Cooper Companies stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $243.88, for a total value of $3,258,724.56. Following the sale, the executive vice president now owns 59,305 shares of the company’s stock, valued at approximately $14,463,303.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 51,846 shares of company stock valued at $12,549,839. Corporate insiders own 1.60% of the company’s stock.

Several brokerages recently weighed in on COO. Zacks Investment Research raised Cooper Companies from a “hold” rating to a “buy” rating and set a $263.00 price objective for the company in a report on Tuesday, May 15th. Raymond James decreased their price objective on Cooper Companies from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Tuesday. Goldman Sachs Group began coverage on Cooper Companies in a report on Wednesday, April 4th. They issued a “neutral” rating and a $231.00 price objective for the company. TheStreet lowered Cooper Companies from a “b” rating to a “c” rating in a report on Thursday, March 8th. Finally, Oppenheimer set a $265.00 target price on Cooper Companies and gave the company a “hold” rating in a report on Friday, March 9th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $265.36.

Cooper Companies Company Profile

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Earnings History for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply